## Boston Scientific Announces Release of Next-Generation iLab® System Software

PRNewswire NATICK, Mass. (NYSE:BSX)

NATICK, Mass., Sept. 21 <u>PRNewswire-FirstCall</u>/ -- Boston Scientific Corporation (NYSE: BSX) today announced release of its CE-Marked, next-generation iLab System Software for the iLab® Ultrasound Imaging System. Intravascular Ultrasound (IVUS) technology is designed to provide physicians a 360-degree view inside the heart and coronary vessels to assist with diagnosis and to allow a more accurate representation of the diseased vessels than is possible with angiography alone. The iLab software upgrade includes functionality designed to improve diagnosis and save time. The principal new feature of the system, iMap<sup>TM</sup>, provides a detailed color analysis of plaque composition within the targeted areas.

"The upgraded iLab software, featuring iMap tissue characterization, offers detailed plaque information that may help physicians treat coronary artery disease," said Prof. Patrick W. Serruys, M.D., Ph.D., Chief of Interventional Cardiology, Thoraxcenter-Erasmus University, Rotterdam. "The combination of Boston Scientific's 40MHz catheter and the new characterization algorithm represents the latest generation of IVUS imaging technology."

In addition to iMap, the iLab software includes features such as Modality Worklist Management, which allows a physician to access a patient's profile from the hospital server and view it on the iLab System monitor. Additional features include an onscreen print icon and the ability to edit and save video images of a procedure directly to CD, DVD or hard drive. The iLab software is currently in a global limited market release with full commercial availability planned for later this year in all regions.

iMap software is not currently approved for sale in the U.S.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: <a href="https://www.bostonscientific.com">www.bostonscientific.com</a>.

## **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding regulatory approvals, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in

the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation

> Larry Neumann 508-650-8696 (office) Investor Relations Boston Scientific Corporation

SOURCE Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

Web site: http://www.bostonscientific.com/

https://news.bostonscientific.com/ilab-system-software-release